CD70-Driven Chronic Immune Activation Is Protective against Atherosclerosisvan Olffen R.W.a · de Bruin A.M.a · Vos M.b · Staniszewska A.D.a · Hamann J.a · van Lier R.A.W.a · de Vries C.J.M.b · Nolte M.A.a
Departments of aExperimental Immunology and bMedical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Dr. Martijn A. Nolte
Department of Experimental Immunology
Academic Medical Center, University of Amsterdam, Meibergdreef 9
NL–1105 AZ Amsterdam (The Netherlands)
Tel. +31 20 566 2226, Fax +31 20 566 9756, E-Mail firstname.lastname@example.org
Do you have an account?
Chronic infection and inflammation are strongly associated with the development of atherosclerosis. To investigate whether chronic inflammation in the absence of an infectious cause also predisposes to the development of atherosclerosis, we used a mouse model in which sterile inflammation is driven by enhanced costimulation. Constitutive triggering of CD27 on T cells through overexpression of CD70 on B cells increases the numbers of IFNγ-producing effector T cells, which reduces the numbers of B cells. However, despite these pro-atherogenic features, we found that CD70-transgenic (CD70TG) mice on an ApoE*3-Leiden background were strongly protected against the induction of atherosclerotic lesions, with a normal increase in serum cholesterol level and the absence of atheroprotective antibodies. We found that circulating monocytes in CD70TG mice were activated and increased in numbers, in particular the pool of inflammatory (Ly6C+) monocytes. Importantly, monocytes from CD70TG mice had no defects in phagocytosis nor in TNFα production, but they were more prone to apoptosis, which was IFNγ-dependent. These data indicate that sterile pro-inflammatory conditions can be protective against atherosclerosis development, possibly due to a reduced viability of circulating monocytes. This unexpected outcome provides a new insight into the consequences of costimulatory signals and their impact on innate immunity.
© 2010 S. Karger AG, Basel
- Becker AE, de Boer OJ, van der Wal AC: The role of inflammation and infection in coronary artery disease. Ann Rev Med 2001;52:289–297.
- Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D: Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol 2000;20:1417–1420.
- Leinonen M and Saikku P: Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2002;2:11–17.
- Hansson GK, Libby P: The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508–519.
- Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA: Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009;229:216–231.
- Hendriks J, Xiao Y, Borst J: CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 2003;198:1369–1380.
- Peperzak V, Xiao Y, Veraar EA, Borst J: CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest 2010;120:168–178.
- Arens R, Tesselaar K, Baars PA, van Schijndel GM, Hendriks J, Pals ST, Krimpenfort P, Borst J, van Oers MH, van Lier RA: Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001;15:801–812.
- Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, van Oers MH: Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med 2004;199:1595–1605.
- Tesselaar K, Arens R, van Schijndel GM, Baars PA, van d, V, Borst J, van Oers MH, van Lier RA: Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol 2003;4:49–54.
- van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, Frants RR, Hofker MH, Havekes LM: Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994;93:1403–1410.
- Caligiuri G, Nicoletti A, Poirier B, Hansson GK: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002;109:745–753.
- Major AS, Fazio S, Linton MF: B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002;22:1892–1898.
- Galkina E, Ley K: Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009;27:165–197.
- Geissmann F, Jung S, Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71–82.
- Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ: Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007;117:195–205.
- Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007;117:185–194.
- Boesten LS, Zadelaar AS, van NA, Gijbels MJ, de Winther MP, Havekes LM, van Vlijmen BJ: Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res 2005;66:179–185.
- Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, Saito K, Sekikawa K, Seishima M: Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005;180:11–17.
- Poot M, Gibson LL, Singer VL: Detection of apoptosis in live cells by MitoTracker red CMXRos and SYTO dye flow cytometry. Cytometry 1997;27:358–364.
- Gautier EL, Jakubzick C, Randolph GJ: Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1412–1418.
- Nolte MA, Arens R, van Os R, van Oosterwijk M, Hooibrink B, van Lier RA, van Oers MH: Immune activation modulates hematopoiesis through interactions between CD27 and CD70. Nat Immunol 2005;6:412–418.
- Stoneman V, Braganza D, Figg N, Mercer J, Lang R, Goddard M, Bennett M: Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res 2007;100:884–893.
- Tabas I: Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010;10:36–46.
- Swirski FK, Weissleder R, Pittet MJ: Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1424–1432.
- Leon ML, Zuckerman SH: Gamma interferon: a central mediator in atherosclerosis. Inflamm Res 2005;54:395–411.
- Canault M, Peiretti F, Poggi M, Mueller C, Kopp F, Bonardo B, Bastelica D, Nicolay A, Alessi MC, Nalbone G: Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha. J Pathol 2008;214:574–583.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.